drugset
drugset / Trial / NCT04269707

Efficacy and Safety of Intravenous Ferric Carboxymaltose in Pediatric Patients With Iron Deficiency Anemia and Unsatisfactory Response Oral Iron Under Study Protocol 1VIT17044

NCT04269707 ↗

Phase 3 Completed 7 enrolled American Regent, Inc.
NaSingle-groupOpen-labelTreatment

Summary

Evaluating the Efficacy and Safety of Intravenous Ferric Carboxymaltose in Pediatric Patients with Iron Deficiency Anemia and an Unsatisfactory Response to Oral Iron under Study Protocol 1VIT17044

Timeline

Start
2019-11-19
Primary completion
2020-12-30
Completion
2021-01-29

Drugs

EvaluationDrugModalityDoseRoute
Subject Ferric carboxymaltose Other / unclassified 15 mg/kg Intravenous

Indications

iron deficiency anemia